The largest database of trusted experimental protocols

Saccharomyces cerevisiae zymosan a

Manufactured by Merck Group
Sourced in United States

Saccharomyces cerevisiae zymosan A is a cell wall preparation derived from the yeast Saccharomyces cerevisiae. It is a complex of carbohydrates, proteins, and lipids that can be used as a research tool in various biological applications.

Automatically generated - may contain errors

4 protocols using saccharomyces cerevisiae zymosan a

1

Purification of Fungal β-Glucan Particles

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fungal β-glucan particles were prepared by treating Saccharomyces cerevisiae zymosan A (Sigma) to remove TLR agonists (depleted zymosan) as previously described (15 (link)). Briefly, zymosan particles were boiled in 10 M NaOH for 30 minutes and then thoroughly washed with PBS and sonicated prior to use. Salmonella minnesota lipopolysaccharide (LPS) was from Invivogen.
+ Open protocol
+ Expand
2

Preparation and Loading of β-Glucan Particles

Check if the same lab product or an alternative is used in the 5 most similar protocols
β-glucan particles were prepared by treating Saccharomyces cerevisiae zymosan A (Sigma) with a hot-alkali treatment to remove TLR agonists as previously described [75 (link)]. Briefly, a suspension of zymosan particles were initially prepared and the particles were then boiled in 10 M NaOH for 1 hour followed by 5 washes in sterile PBS. The glucan particles were then dried in a Savant SpeedVac vacuum concentrator. Dried glucan particles were loaded with various concentrations of ovalbumin (OVA) or the recombinant S. aureus proteins (with or without TRITC or FITC-labeling) as previously described [29 (link), 51 (link)]. Glucan particles (GPs) were kept as frozen aliquots and were sonicated in an ultrasonic water bath for 15 minutes prior to their in vitro or in vivo use. Empty-GPs were prepared the same as the loaded-GPs minus the addition of any protein antigen.
+ Open protocol
+ Expand
3

Modulation of BMDC Activation by Helminth Larvae

Check if the same lab product or an alternative is used in the 5 most similar protocols
1 x 106 BMDCs were plated in 24 well-plates (Nunc, Roskilde, Denmark) in complete RPMI medium. 5, 20 or 50 axenically maintained larvae were washed thrice and added directly into DC cultures. In another series of experiments, larvae were separated from BMDCs using trans-well inserts (0.4 μm, BD Falcon). Alternatively, larva ES products were used instead of whole larvae. Lipopolysacharide (LPS; 0.1 μg/ml, E. coli 0127:B8) was used as a positive control for DC activation. After 24h of DC stimulation at 37°C under 5% CO2, supernatants were collected for cytokine detection and cells were stained for flow cytometric analysis. For re-stimulation experiments, larvae were removed 24 h post stimulation and BMDCs were further stimulated with LPS (0.1 μg/ml, E. coli 0127:B8) for an additional 24 h. In some experiments, BMDCs were treated with different doses (0.5 μg/ml up to 50 μg/ml) of M. corti ES products or McH prior to, at the same time with, or 18 h after LPS stimulation. In several experiments different stimuli were used instead of LPS for restimulation i.e.: Zymosan A (Saccharomyces cerevisiae; 50 μg/ml, Sigma), Curdlan (50 μg/ml, Wako), Lipotechoic acid (LTA, 10 μg/ml, InvivoGen) or phorbol 12-myristate 13-acetate (PMA; 0.5 μg/ml, Sigma). Control BMDC wells were treated in a similar way without exposure to parasite larva samples.
+ Open protocol
+ Expand
4

Modeling Acute Lung Injury in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Intra-and extrapulmonary ALI models, matched for lung injury severity, were produced in this study. The anesthetized mice in the extrapulmonary ALI models received 3 mg/kg LPS (Escherichia coli 0111:B4; Sigma-Aldrich, St. Louis, MO, USA) intravenously (IV) and 10 mg/kg zymosan A (Saccharomyces cerevisiae; Sigma-Aldrich) IV 2 h later (22) (23) (24) . The anesthetized mice in the intrapulmonary ALI model received intratracheal (IT) LPS at 0, 1, 2, 3, 4, or 5 mg/kg. The mice were sacrificed 4 h after the LPS/zymosan IV or LPS IT challenge, and lung tissues were collected for analyses. Lung histopathology was evaluated with hematoxylin and eosin (Beyotime Institute of Biotechnology, Haimen, China) staining, and lung edema was measured using the lung wet weight/body weight ratio (LWW/BW) to match the severity of the lung injury.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!